And the maker of that treatment, Autolus, is worth less than NWBO on the market.
Take a look at their valuation since approval. -67% since November 8 with obe-cel was approved.
Still, no one believes that these biotechs can go down after approval. Down another 4% on announcing obe-cel approval in the UK.
Obviously different markets and competitive landscapes, but if you think it's impossible for NWBO to go down upon announcing approval, you are not paying attention.
Market Data 
Markets 
AI
